Importantly, this dependency creates a therapeutic vulnerability: pharmacological inhibition of antioxidant components—such as GPX4, Trx1, TrxR, and SOD1—can tip the balance toward lethal oxidative stress and selectively kill tumor cells. Here, GPX4 is linked to neoplasm.